Mike heads Defined Health’s Advanced Therapies and Rare Diseases practices. He also co-heads the oncology practice focusing on hematologic malignancies and genetically defined cancers.
He has 20 years’ experience in biotech ventures defining strategic development and early commercial strategy for academic and biotech inventions pertaining to nucleic acids, gene therapy and cellular platforms applied across monogenetic diseases and oncology.
Mike studied molecular pharmacology, cancer genetics and the role of recombinational DNA repair enzymes such as RAD51 paralogs at Thomas Jefferson University’s Kimmel Cancer Institute. His thesis research led to pioneering gene editing technologies which served the basis of several gene therapy, diagnostics, and agribiotechnology firms. Mike holds an MBA, with a concentration in Biotechnology, from the Alfred Lerner School of Business and Economics, at the University of Delaware
Mike is a member of the American Society of Gene and Cell Therapy (ASGCT), the Alliance for Regenerative Medicine (ARM), the Society for Immunotherapy of Cancer (SITC), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the Licensing Executives Society (LES), and the American Heart Association (AHA)
There are two parts to the World Advanced Therapies & Regenerative Medicine Congress: a conference and an exhibition featuring solutions for pharma and biotech.
There is a registration fee to attend the conferences. To visit the exhibition is free.